Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=5
{ "count": 24503, "next": "http://api.gregory-ms.com/articles/?format=api&page=6", "previous": "http://api.gregory-ms.com/articles/?format=api&page=4", "results": [ { "article_id": 283328, "title": "Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study", "summary": "<jats:title>Abstract</jats:title><jats:sec>\n <jats:title>Background</jats:title>\n <jats:p>Mesenchymal stem cells (MSCs) hold a great promise for cell-based therapy in the field of regenerative medicine. In this study, we aimed to evaluate the safety and efficacy of intravenous infusion of human umbilical cord-derived MSCs (HUC-MSCs) in patients with aging frailty.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Methods</jats:title>\n <jats:p>In this randomized, double-blind, placebo-controlled trial, participants diagnosed with aging frailty were randomly assigned to receive intravenous administrations of HUC-MSCs or placebo. All of serious adverse events and AEs were monitored to evaluate the safety of treatment during the 6-month follow-up. The primary efficacy endpoint was alteration of physical component scores (PCS) of SF-36 qualities of life at 6 months. The secondary outcomes including physical performance tests and pro-inflammatory cytokines, were also observed and compared at each follow-up visits. All evaluations were performed at 1 week, 1, 2, 3 and 6 months following the first intravenous infusion of HUC-MSCs.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Results</jats:title>\n <jats:p>In the MSCs group, significant improvements in PCS of SF-36 were observed from first post-treatment visit and sustained throughout the follow-up period, with greater changes compared to the placebo group (<jats:italic>p</jats:italic> = 0.042). EQ-VAS scores of MSCs group improved significantly at 2 month (<jats:italic>p</jats:italic> = 0.023) and continued until the end of the 6-month visit (<jats:italic>p</jats:italic> = 0.002) in comparison to the placebo group. The timed up and go (TUG) physical performance test revealed significant group difference and showed continual enhancements over 6 months (<jats:italic>p</jats:italic> < 0.05). MSC transplantation improved the function of 4-m walking test (4MWT) compared with the placebo group with a decrease of 2.05 s at 6 months of follow-up (<jats:italic>p</jats:italic> = 0.21). The measurement of grip strength revealed group difference with MSCs group demonstrating better performance, particularly at 6 months (<jats:italic>p</jats:italic> = 0.002). Inflammatory cytokines (TNF-α, IL-17) exhibited declines in MSCs group at 6 months compared to the placebo group (<jats:italic>p</jats:italic> = 0.034 and 0.033, respectively). There was no difference of incidence of AEs between the two groups.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Conclusion</jats:title>\n <jats:p>Intravenous transplantation of HUC-MSCs is a safe and effective therapeutic approach on aging frailty. The positive outcomes observed in improving quality of life, physical performance, and reducing chronic inflammation, suggest that HUC-MSC therapy may be a promising potential treatment option for aging frailty.</jats:p>\n <jats:p><jats:italic>Trial Registration</jats:italic>: Clinicaltrial.gov; NCT04314011; <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://clinicaltrials.gov/ct2/show/NCT04314011\">https://clinicaltrials.gov/ct2/show/NCT04314011</jats:ext-link>.</jats:p>\n </jats:sec>", "link": "https://stemcellres.biomedcentral.com/articles/10.1186/s13287-024-03707-2", "published_date": "2024-04-28T23:00:00Z", "source": "BioMedCentral", "publisher": "Springer Science and Business Media LLC", "container_title": "Stem Cell Research & Therapy", "authors": [ { "author_id": 349395, "given_name": "Yingqian", "family_name": "Zhu", "ORCID": "http://orcid.org/0000-0001-7452-1536", "country": null }, { "author_id": 333003, "given_name": "Ce", "family_name": "Huang", "ORCID": null, "country": null }, { "author_id": 349396, "given_name": "Liang", "family_name": "Zheng", "ORCID": null, "country": null }, { "author_id": 349397, "given_name": "Qingqing", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 349398, "given_name": "Jianli", "family_name": "Ge", "ORCID": null, "country": null }, { "author_id": 349399, "given_name": "ShaSha", "family_name": "Geng", "ORCID": null, "country": null }, { "author_id": 349400, "given_name": "Miaomiao", "family_name": "Zhai", "ORCID": null, "country": null }, { "author_id": 201623, "given_name": "Xin", "family_name": "Chen", "ORCID": "http://orcid.org/0000-0002-5406-4136", "country": "CN" }, { "author_id": 349401, "given_name": "Huixiao", "family_name": "Yuan", "ORCID": null, "country": null }, { "author_id": 349402, "given_name": "Wenwen", "family_name": "Jia", "ORCID": null, "country": null }, { "author_id": 349403, "given_name": "Keping", "family_name": "Sun", "ORCID": null, "country": null }, { "author_id": 349404, "given_name": "Tong", "family_name": "Ye", "ORCID": null, "country": null }, { "author_id": 349405, "given_name": "Zhengmei", "family_name": "Zhao", "ORCID": null, "country": null }, { "author_id": 333005, "given_name": "Hailiang", "family_name": "Liu", "ORCID": null, "country": null }, { "author_id": 349406, "given_name": "Zhongmin", "family_name": "Liu", "ORCID": null, "country": null }, { "author_id": 308620, "given_name": "Hua", "family_name": "Jiang", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-29T04:26:48.679180Z", "noun_phrases": null, "doi": "10.1186/s13287-024-03707-2", "access": "restricted", "takeaways": null, "categories": [ { "category_id": 12, "category_description": "Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and other stem cell therapies", "category_name": "Stem Cells", "category_slug": "stem-cells", "category_terms": [ "stem cells", "Autologous hematopoietic stem cell", "ahsct" ], "article_count": 228 } ] }, { "article_id": 283323, "title": "The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases", "summary": "<jats:sec>\n<jats:title>Abstract:</jats:title>\n<jats:p>Sphingosine 1-phosphate (S1P) is extensively researched as a lysophospholipid and is crucial in various physiological and pathological processes. It achieves this via signalling through five different subtypes of G protein-coupled receptors (GPCRs), namely S1PR1 to S1PR5. S1PR modulators possess the ability to traverse the blood-brain barrier, potentially leading to direct ac-tions within the Central Nervous System (CNS). S1PR modulators specifically bind to receptors located on the surface of naive and central memory lymphocytes, causing these cells to be trapped or confined within the lymph node. The investigation of the S1P pathway has resulted in the ap-proval of three S1PR modulators, namely fingolimod, siponimod, and ozanimod, as medications for the treatment of patients suffering from Multiple Sclerosis (MS). Additionally, new S1PR modulators, such as ponesimod and etrasimod, are currently being developed and tested in clini-cal trials. Research on the creation of S1P modulators in neurodegenerative illnesses is ongoing as scientists continue to explore novel possibilities for selective S1P modulators. This study provides a concise overview of sphingolipid metabolism, the mechanism by which S1P receptors are af-fected, and the structural characteristics of several small molecule S1P modulators, with a particu-lar focus on their structure-activity connections.</jats:p>\n</jats:sec>", "link": "https://pubmed.ncbi.nlm.nih.gov/38676503/?fc=20210216052009&ff=20240429062536&v=2.18.0.post9+e462414", "published_date": "2024-04-27T10:00:00Z", "source": "PubMed", "publisher": "Bentham Science Publishers Ltd.", "container_title": "Current Topics in Medicinal Chemistry", "authors": [ { "author_id": 349291, "given_name": "Sidharth", "family_name": "Sankar Kar", "ORCID": null, "country": null }, { "author_id": 349292, "given_name": "Soumya Ranjan", "family_name": "Gharai", "ORCID": null, "country": null }, { "author_id": 349293, "given_name": "Sujit Kumar", "family_name": "Sahu", "ORCID": null, "country": null }, { "author_id": 349294, "given_name": "V.", "family_name": "Ravichandiran", "ORCID": null, "country": null }, { "author_id": 349295, "given_name": "Sharada Prasanna", "family_name": "Swain", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-28T11:25:39.118284Z", "noun_phrases": null, "doi": "10.2174/0115680266288509240422112839", "access": "restricted", "takeaways": "Sphingosine 1-phosphate (S1P) is a lysophospholipid that is crucial in various physiological and pathological processes. S1PR modulators possess the ability to traverse the blood-brain barrier, potentially leading to direct ac-tions within the Central Nervous System (CNS). They bind to receptors located on the surface of naive and central memory lymphocytes, causing these cells to be trapped or confined within", "categories": [] }, { "article_id": 283322, "title": "Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS", "summary": "CONCLUSION: The results of the BCD-132-4/MIRANTIBUS CT indicate a high sustained efficacy and safety of long-term use of DIV in comparison with TRF during 2 years of therapy.", "link": "https://pubmed.ncbi.nlm.nih.gov/38676683/?fc=20210216052009&ff=20240429062536&v=2.18.0.post9+e462414", "published_date": "2024-04-27T10:00:00Z", "source": "PubMed", "publisher": "Media Sphere Publishing Group", "container_title": "S.S. Korsakov Journal of Neurology and Psychiatry", "authors": [ { "author_id": 313440, "given_name": "A.N.", "family_name": "Boyko", "ORCID": "http://orcid.org/0000-0003-4731-3250", "country": null }, { "author_id": 211305, "given_name": "V.M.", "family_name": "Alifirova", "ORCID": "http://orcid.org/0000-0002-4140-3223", "country": null }, { "author_id": 313441, "given_name": "I.G.", "family_name": "Lukashevich", "ORCID": "http://orcid.org/0000-0003-0237-8624", "country": null }, { "author_id": 167053, "given_name": "Z.A.", "family_name": "Goncharova", "ORCID": "http://orcid.org/0000-0001-7093-9548", "country": null }, { "author_id": 313442, "given_name": "I.V.", "family_name": "Greshnova", "ORCID": "http://orcid.org/0000-0003-3092-5381", "country": null }, { "author_id": 205696, "given_name": "L.G.", "family_name": "Zaslavsky", "ORCID": "http://orcid.org/0000-0001-9912-1512", "country": null }, { "author_id": 313392, "given_name": "S.V.", "family_name": "Kotov", "ORCID": "http://orcid.org/0000-0002-8706-7317", "country": null }, { "author_id": 161120, "given_name": "N.A.", "family_name": "Malkova", "ORCID": "http://orcid.org/0000-0002-1255-8525", "country": null }, { "author_id": 313443, "given_name": "G.N.", "family_name": "Mishin", "ORCID": "http://orcid.org/0000-0001-5111-0881", "country": null }, { "author_id": 205697, "given_name": "Ye.V.", "family_name": "Parshina", "ORCID": "http://orcid.org/0000-0001-7033-053X", "country": "RU" }, { "author_id": 205698, "given_name": "I.Ye.", "family_name": "Poverennova", "ORCID": "http://orcid.org/0000-0002-2594-461X", "country": null }, { "author_id": 179516, "given_name": "L.N.", "family_name": "Prakhova", "ORCID": "http://orcid.org/0000-0002-4776-2999", "country": null }, { "author_id": 161121, "given_name": "S.A.", "family_name": "Sivertseva", "ORCID": "http://orcid.org/0000-0002-9293-5932", "country": null }, { "author_id": 313376, "given_name": "I.V.", "family_name": "Smagina", "ORCID": "http://orcid.org/0000-0002-7947-4529", "country": "RU" }, { "author_id": 167052, "given_name": "N.A.", "family_name": "Totolyan", "ORCID": "http://orcid.org/0000-0002-6715-8203", "country": null }, { "author_id": 313444, "given_name": "Yu.V.", "family_name": "Trinitatsky", "ORCID": "http://orcid.org/0000-0001-9680-7308", "country": null }, { "author_id": 313445, "given_name": "T.N.", "family_name": "Trushnikova", "ORCID": "http://orcid.org/0000-0001-9199-7392", "country": null }, { "author_id": 167051, "given_name": "F.A.", "family_name": "Khabirov", "ORCID": "http://orcid.org/0000-0002-2572-6970", "country": "RU" }, { "author_id": 313446, "given_name": "J.Yu.", "family_name": "Chefranova", "ORCID": "http://orcid.org/0000-0002-2106-7461", "country": null }, { "author_id": 205699, "given_name": "S.G.", "family_name": "Shchur", "ORCID": "http://orcid.org/0000-0002-1715-0465", "country": null }, { "author_id": 313447, "given_name": "V.A.", "family_name": "Dudin", "ORCID": "http://orcid.org/0000-0002-5624-240X", "country": null }, { "author_id": 313448, "given_name": "D.V.", "family_name": "Pokhabov", "ORCID": "http://orcid.org/0000-0001-5895-5043", "country": null }, { "author_id": 324975, "given_name": "A.V.", "family_name": "Artemyeva", "ORCID": "http://orcid.org/0000-0002-5306-3377", "country": null }, { "author_id": 313449, "given_name": "A.V.", "family_name": "Eremeeva", "ORCID": "http://orcid.org/0000-0001-5196-6911", "country": null }, { "author_id": 205703, "given_name": "Yu.N.", "family_name": "Linkova", "ORCID": "http://orcid.org/0000-0002-5463-1022", "country": null }, { "author_id": 205702, "given_name": "A.V.", "family_name": "Zinkina-Orikhan", "ORCID": "http://orcid.org/0000-0002-8499-2232", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-28T11:25:37.647289Z", "noun_phrases": null, "doi": "10.17116/jnevro202412404186", "access": "restricted", "takeaways": "", "categories": [] }, { "article_id": 283321, "title": "A case of COVID-associated encephalopathy in a patient with multiple sclerosis", "summary": "A case of acute encephalopathy manifested with impaired consciousness, hemichorrhea, speech and cognitive impairment in a female patient with COVID-19 and multiple sclerosis is presented. In the literature, there are isolated reports of such a combination of diseases, and therefore difficulties arise in carrying out differential diagnosis and prescribing therapy. Given the limited knowledge about the long-term consequences of COVID-19, systematic analysis of such cases and follow-up of such...", "link": "https://pubmed.ncbi.nlm.nih.gov/38676691/?fc=20210216052009&ff=20240429062536&v=2.18.0.post9+e462414", "published_date": "2024-04-27T10:00:00Z", "source": "PubMed", "publisher": "Media Sphere Publishing Group", "container_title": "S.S. Korsakov Journal of Neurology and Psychiatry", "authors": [ { "author_id": 330853, "given_name": "U.Sh.", "family_name": "Kuzmina", "ORCID": "http://orcid.org/0000-0001-7056-7895", "country": null }, { "author_id": 330854, "given_name": "A.V.", "family_name": "Tukhvatullin", "ORCID": "http://orcid.org/0000-0002-5051-2683", "country": null }, { "author_id": 313275, "given_name": "O.V.", "family_name": "Lyutov", "ORCID": "http://orcid.org/0000-0003-1393-1122", "country": null }, { "author_id": 349288, "given_name": "I.D.", "family_name": "Talipova", "ORCID": "http://orcid.org/0009-0009-1064-6589", "country": null }, { "author_id": 349289, "given_name": "E.N.", "family_name": "Zakirova", "ORCID": "http://orcid.org/0000-0002-8199-0741", "country": null }, { "author_id": 349290, "given_name": "A.R.", "family_name": "Rakhmatullin", "ORCID": "http://orcid.org/0000-0002-8342-3943", "country": null }, { "author_id": 330855, "given_name": "M.A.", "family_name": "Kutlubaev", "ORCID": "http://orcid.org/0000-0003-1001-2024", "country": null }, { "author_id": 161119, "given_name": "K.Z.", "family_name": "Bakhtiyarova", "ORCID": "http://orcid.org/0000-0003-0982-4324", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-28T11:25:36.540003Z", "noun_phrases": null, "doi": "10.17116/jnevro2024124041159", "access": "restricted", "takeaways": "There is a case of acute encephalopathy in a female patient with COVID-19 and multiple sclerosis. There is limited knowledge about the long", "categories": [] }, { "article_id": 283320, "title": "Dietary Modification Combined with Nutrition Education and Counseling for Metabolic Comorbidities in Multiple Sclerosis: Implications for Clinical Practice and Research", "summary": "<jats:title>Abstract</jats:title><jats:sec>\n<jats:title>Purpose of Review</jats:title>\n<jats:p>Metabolic comorbidities such as obesity, diabetes, hypertension, and dyslipidemia are common to multiple sclerosis (MS) and are associated with negative outcomes of the disease. Dietary intervention has the potential to improve MS co-morbidities; thus, it is a high priority for people living with MS to self-manage their disease. The present review aimed to summarize the recent evidence on the impacts of combining dietary modification with nutrition education and counseling on managing metabolic comorbidity markers in MS.</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Recent Findings</jats:title>\n<jats:p> Evidence suggests important roles for tailored dietary change strategies and nutrition education and counseling in managing metabolic comorbidities for MS. There is also indirect evidence suggesting a relationship between dietary fiber, the gut microbiome, and improved metabolic markers in MS, highlighting the need for more research in this area. For people living with MS, addressing both barriers and facilitators to dietary changes through behavior change techniques can help them achieve sustainable and tailored dietary behavior changes. This will support person-centered care, ultimately improving metabolic comorbidity outcomes.</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Summary</jats:title>\n<jats:p>Metabolic comorbidities in MS are considered modifiable diseases that can be prevented and managed by changes in dietary behavior. However, the impact of targeted dietary interventions on mitigating MS-related metabolic comorbidities remains inadequately explored. Therefore, this review has provided insights into recommendations to inform future best practices in MS. Further well-designed studies based on tailored dietary strategies applying behavior change theories are needed to address the underlying determinants of dietary practice in this population.</jats:p>\n</jats:sec>", "link": "https://pubmed.ncbi.nlm.nih.gov/38676838/?fc=20210216052009&ff=20240429062536&v=2.18.0.post9+e462414", "published_date": "2024-04-27T10:00:00Z", "source": "PubMed", "publisher": "Springer Science and Business Media LLC", "container_title": "Current Nutrition Reports", "authors": [ { "author_id": 349287, "given_name": "Shoroog", "family_name": "Allogmanny", "ORCID": "http://orcid.org/0009-0000-1197-0676", "country": "SA" }, { "author_id": 158959, "given_name": "Yasmine", "family_name": "Probst", "ORCID": "http://orcid.org/0000-0002-1971-173X", "country": "AU" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-28T11:25:35.572342Z", "noun_phrases": null, "doi": "10.1007/s13668-024-00538-8", "access": "open", "takeaways": "Dietary intervention can improve MS co-morbidities such as obesity, diabetes, hypertension, and dyslipidemia. There is indirect evidence that there is a relationship between dietary fiber and improved metabolic markers in MS.", "categories": [] }, { "article_id": 283319, "title": "Neurodegenerative disease pathways are perturbed in patients with cancer who self‐report cognitive changes and anxiety: A pathway impact analysis", "summary": "<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Cancer‐related cognitive impairment (CRCI) and anxiety co‐occur in patients with cancer. Little is known about mechanisms for the co‐occurrence of these two symptoms. The purposes of this secondary analysis were to evaluate for perturbed pathways associated with the co‐occurrence of self‐reported CRCI and anxiety in patients with low versus high levels of these two symptoms and to identify potential mechanisms for the co‐occurrence of CRCI and anxiety using biological processes common across any perturbed neurodegenerative disease pathways.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients completed the Attentional Function Index and the Spielberger State‐Trait Anxiety Inventory six times over two cycles of chemotherapy. Based on findings from a previous latent profile analysis, patients were grouped into none versus both high levels of these symptoms. Gene expression was quantified, and pathway impact analyses were performed. Signaling pathways for evaluation were defined with the Kyoto Encyclopedia of Genes and Genomes database.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 451 patients had data available for analysis. Approximately 85.0% of patients were in the none class and 15.0% were in the both high class. Pathway impact analyses identified five perturbed pathways related to neurodegenerative diseases (i.e., amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, prion disease, and pathways of neurodegeneration–multiple diseases). Apoptosis, mitochondrial dysfunction, oxidative stress, and endoplasmic reticulum stress were common biological processes across these pathways.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This study is the first to describe perturbations in neurodegenerative disease pathways associated with CRCI and anxiety in patients receiving chemotherapy. These findings provide new insights into potential targets for the development of mechanistically based interventions.</jats:p></jats:sec>", "link": "https://pubmed.ncbi.nlm.nih.gov/38676932/?fc=20210216052009&ff=20240429062536&v=2.18.0.post9+e462414", "published_date": "2024-04-27T10:00:00Z", "source": "PubMed", "publisher": "Wiley", "container_title": "Cancer", "authors": [ { "author_id": 349273, "given_name": "Kate R.", "family_name": "Oppegaard", "ORCID": "http://orcid.org/0000-0002-6358-6315", "country": null }, { "author_id": 349274, "given_name": "Samantha J.", "family_name": "Mayo", "ORCID": "http://orcid.org/0000-0002-0083-5679", "country": "CA" }, { "author_id": 349275, "given_name": "Terri S.", "family_name": "Armstrong", "ORCID": "http://orcid.org/0000-0002-2414-0492", "country": null }, { "author_id": 349276, "given_name": "Vasuda", "family_name": "Dokiparthi", "ORCID": null, "country": null }, { "author_id": 349277, "given_name": "Michelle", "family_name": "Melisko", "ORCID": null, "country": null }, { "author_id": 349278, "given_name": "Jon D.", "family_name": "Levine", "ORCID": "http://orcid.org/0000-0003-0681-5545", "country": null }, { "author_id": 349279, "given_name": "Adam B.", "family_name": "Olshen", "ORCID": null, "country": null }, { "author_id": 170257, "given_name": "Joaquin A", "family_name": "Anguera", "ORCID": "http://orcid.org/0000-0002-7216-0674", "country": null }, { "author_id": 349280, "given_name": "Ritu", "family_name": "Roy", "ORCID": "http://orcid.org/0000-0003-2065-7846", "country": null }, { "author_id": 349281, "given_name": "Steven", "family_name": "Paul", "ORCID": "http://orcid.org/0000-0002-3731-683X", "country": "US" }, { "author_id": 349282, "given_name": "Bruce", "family_name": "Cooper", "ORCID": "http://orcid.org/0000-0001-8932-4113", "country": null }, { "author_id": 349283, "given_name": "Yvette P.", "family_name": "Conley", "ORCID": "http://orcid.org/0000-0002-1784-6067", "country": null }, { "author_id": 349284, "given_name": "Marilyn J.", "family_name": "Hammer", "ORCID": "http://orcid.org/0000-0002-9561-6144", "country": null }, { "author_id": 349285, "given_name": "Christine", "family_name": "Miaskowski", "ORCID": "http://orcid.org/0000-0001-5170-2027", "country": null }, { "author_id": 349286, "given_name": "Kord M.", "family_name": "Kober", "ORCID": "http://orcid.org/0000-0001-9732-3321", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-28T11:25:34.238750Z", "noun_phrases": null, "doi": "10.1002/cncr.35336", "access": "restricted", "takeaways": "Cancer-related cognitive impairment (CRCI) and anxiety co-occur in cancer patients. This study is the first to describe perturbations in neurodegenerative disease pathways associated with CRCI and anxiety in patients receiving chemotherapy. The findings provide new insights into potential targets for the development of mechanistically based interventions.", "categories": [] }, { "article_id": 283318, "title": "Decreased exercise-induced natural killer cell redistribution in multiple sclerosis", "summary": "CONCLUSION: Exercise-induced redeployment of NK cells may be reduced in MS patients, as well as their migration capabilities, pointing to potential immunological mechanisms to be enhanced by exercise training programs.", "link": "https://pubmed.ncbi.nlm.nih.gov/38677127/?fc=20210216052009&ff=20240429062536&v=2.18.0.post9+e462414", "published_date": "2024-04-27T10:00:00Z", "source": "PubMed", "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 289563, "given_name": "Elvira", "family_name": "Munteis", "ORCID": null, "country": null }, { "author_id": 298909, "given_name": "Andrea", "family_name": "Vera", "ORCID": null, "country": null }, { "author_id": 349268, "given_name": "Mireia", "family_name": "Llop", "ORCID": null, "country": null }, { "author_id": 349269, "given_name": "Antía", "family_name": "Moreira", "ORCID": null, "country": null }, { "author_id": 349270, "given_name": "Guillermo R.", "family_name": "Oviedo", "ORCID": null, "country": null }, { "author_id": 349271, "given_name": "Casimiro", "family_name": "Javierre", "ORCID": null, "country": null }, { "author_id": 349272, "given_name": "Jose E.", "family_name": "Martínez-Rodríguez", "ORCID": "http://orcid.org/0000-0001-6765-5587", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-28T11:25:32.999601Z", "noun_phrases": null, "doi": "10.1016/j.msard.2024.105634", "access": "open", "takeaways": "", "categories": [] }, { "article_id": 283317, "title": "Antipsychotic medications associated with increased length of hospital stay in autoimmune encephalitis and multiple sclerosis: A retrospective study", "summary": "CONCLUSIONS: There was a statistically significant increase in LOS associated with APM use in non-infectious encephalitis and MS, as well as with SSRI use in MS. These data reflect the importance of these medications in these neuroinflammatory disorders and suggest that further investigation into their risks and benefits would be warranted.", "link": "https://pubmed.ncbi.nlm.nih.gov/38677201/?fc=20210216052009&ff=20240429062536&v=2.18.0.post9+e462414", "published_date": "2024-04-27T10:00:00Z", "source": "PubMed", "publisher": "Elsevier BV", "container_title": "Journal of Clinical Neuroscience", "authors": [ { "author_id": 349264, "given_name": "Stephen", "family_name": "Sai Folmsbee", "ORCID": null, "country": null }, { "author_id": 349265, "given_name": "Gavin", "family_name": "Hui", "ORCID": null, "country": null }, { "author_id": 315100, "given_name": "Ye", "family_name": "Yuan", "ORCID": null, "country": null }, { "author_id": 349266, "given_name": "Saurabh", "family_name": "Gombar", "ORCID": null, "country": null }, { "author_id": 256704, "given_name": "May", "family_name": "Han", "ORCID": null, "country": null }, { "author_id": 349267, "given_name": "Scheherazade", "family_name": "Le", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-28T11:25:31.770613Z", "noun_phrases": null, "doi": "10.1016/j.jocn.2024.04.021", "access": "restricted", "takeaways": "", "categories": [] }, { "article_id": 283312, "title": "Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI", "summary": "<jats:title>Abstract</jats:title><jats:sec>\n <jats:title>Background</jats:title>\n <jats:p>Identifying individuals with intracranial injuries following mild traumatic brain injury (mTBI), i.e. complicated mTBI cases, is important for follow-up and prognostication. The main aims of our study were (1) to assess the temporal evolution of blood biomarkers of CNS injury and inflammation in individuals with complicated mTBI determined on computer tomography (CT) and magnetic resonance imaging (MRI); (2) to assess the corresponding discriminability of both single- and multi-biomarker panels, from acute to chronic phases after injury.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Methods</jats:title>\n <jats:p>Patients with mTBI (<jats:italic>n</jats:italic> = 207), defined as Glasgow Coma Scale score between 13 and 15, loss of consciousness < 30 min and post-traumatic amnesia < 24 h, were included. Complicated mTBI – i.e., presence of any traumatic intracranial injury on neuroimaging – was present in 8% (<jats:italic>n</jats:italic> = 16) on CT (CT+) and 12% (<jats:italic>n</jats:italic> = 25) on MRI (MRI+). Blood biomarkers were sampled at four timepoints following injury: admission (within 72 h), 2 weeks (± 3 days), 3 months (± 2 weeks) and 12 months (± 1 month). CNS biomarkers included were glial fibrillary acidic protein (GFAP), neurofilament light (NFL) and tau, along with 12 inflammation markers.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Results</jats:title>\n <jats:p>The most discriminative single biomarkers of traumatic intracranial injury were GFAP at admission (CT+: AUC = 0.78; MRI+: AUC = 0.82), and NFL at 2 weeks (CT+: AUC = 0.81; MRI+: AUC = 0.89) and 3 months (MRI+: AUC = 0.86). MIP-1β and IP-10 concentrations were significantly lower across follow-up period in individuals who were CT+ and MRI+. Eotaxin and IL-9 were significantly lower in individuals who were MRI+ only. FGF-basic concentrations increased over time in MRI- individuals and were significantly higher than MRI+ individuals at 3 and 12 months. Multi-biomarker panels improved discriminability over single biomarkers at all timepoints (AUCs > 0.85 for admission and 2-week models classifying CT+ and AUC ≈ 0.90 for admission, 2-week and 3-month models classifying MRI+).</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Conclusions</jats:title>\n <jats:p>The CNS biomarkers GFAP and NFL were useful single diagnostic biomarkers of complicated mTBI, especially in acute and subacute phases after mTBI. Several inflammation markers were suppressed in patients with complicated versus uncomplicated mTBI and remained so even after 12 months. Multi-biomarker panels improved diagnostic accuracy at all timepoints, though at acute and 2-week timepoints, the single biomarkers GFAP and NFL, respectively, displayed similar accuracy compared to multi-biomarker panels.</jats:p>\n </jats:sec>", "link": "https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-024-03094-8", "published_date": "2024-04-26T23:00:00Z", "source": "BioMedCentral", "publisher": "Springer Science and Business Media LLC", "container_title": "Journal of Neuroinflammation", "authors": [ { "author_id": 349258, "given_name": "Gerard Janez Brett", "family_name": "Clarke", "ORCID": null, "country": null }, { "author_id": 349259, "given_name": "Turid", "family_name": "Follestad", "ORCID": null, "country": null }, { "author_id": 349260, "given_name": "Toril", "family_name": "Skandsen", "ORCID": null, "country": null }, { "author_id": 349261, "given_name": "Anne", "family_name": "Vik", "ORCID": null, "country": null }, { "author_id": 349262, "given_name": "Alexander", "family_name": "Olsen", "ORCID": null, "country": null }, { "author_id": 349263, "given_name": "Asta Kristine", "family_name": "Håberg", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-27T20:27:08.483508Z", "noun_phrases": null, "doi": "10.1186/s12974-024-03094-8", "access": "restricted", "takeaways": null, "categories": [] }, { "article_id": 283311, "title": "Obesity-induced blood-brain barrier dysfunction: phenotypes and mechanisms", "summary": "<jats:title>Abstract</jats:title><jats:p>Obesity, a burgeoning global health issue, is increasingly recognized for its detrimental effects on the central nervous system, particularly concerning the integrity of the blood-brain barrier (BBB). This manuscript delves into the intricate relationship between obesity and BBB dysfunction, elucidating the underlying phenotypes and molecular mechanisms. We commence with an overview of the BBB’s critical role in maintaining cerebral homeostasis and the pathological alterations induced by obesity. By employing a comprehensive literature review, we examine the structural and functional modifications of the BBB in the context of obesity, including increased permeability, altered transport mechanisms, and inflammatory responses. The manuscript highlights how obesity-induced systemic inflammation and metabolic dysregulation contribute to BBB disruption, thereby predisposing individuals to various neurological disorders. We further explore the potential pathways, such as oxidative stress and endothelial cell dysfunction, that mediate these changes. Our discussion culminates in the summary of current findings and the identification of knowledge gaps, paving the way for future research directions. This review underscores the significance of understanding BBB dysfunction in obesity, not only for its implications in neurodegenerative diseases but also for developing targeted therapeutic strategies to mitigate these effects.</jats:p>", "link": "https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-024-03104-9", "published_date": "2024-04-26T23:00:00Z", "source": "BioMedCentral", "publisher": "Springer Science and Business Media LLC", "container_title": "Journal of Neuroinflammation", "authors": [ { "author_id": 349203, "given_name": "Ziying", "family_name": "Feng", "ORCID": null, "country": null }, { "author_id": 349204, "given_name": "Cheng", "family_name": "Fang", "ORCID": null, "country": null }, { "author_id": 349205, "given_name": "Yinzhong", "family_name": "Ma", "ORCID": null, "country": null }, { "author_id": 349206, "given_name": "Junlei", "family_name": "Chang", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-27T20:26:58.514703Z", "noun_phrases": null, "doi": "10.1186/s12974-024-03104-9", "access": "restricted", "takeaways": "Obesity has detrimental effects on the central nervous system, particularly concerning the integrity of the blood-brain barrier (BBB). This manuscript delves into the relationship between obesity and BBB dysfunction. It highlights how obesity-induced systemic inflammation and metabolic dysregulation contribute to BBB disruption.", "categories": [] } ] }